Table 2 Adverse events reported during the study
Adverse events | Group A - 0.6Â mg | Group B - 1.2Â mg | Group C - 1.8Â mg | Group D - 2.4Â mg | ||||
|---|---|---|---|---|---|---|---|---|
n = 3 | n = 3 | n = 3 | n = 3 | |||||
AEs | Patients | AEs | Patients | AEs | Patients | AEs | Patients | |
White blood cell decreased | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
ALT increased | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
Neutrophil count decreased | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
AST increased | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Hemoglobin increased | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Headache | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 0 |
Dizziness | 4 | 2 | 4 | 3 | 5 | 3 | 0 | 0 |
Temporary amaurosis | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
Cough | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Upper respiratory infection | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Hyperhidrosis | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Fever | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
Tremors | 0 | 0 | 2 | 1 | 2 | 1 | 0 | 0 |
Face flushing | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Injection site erythema | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 |
Injection site itching | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
injection site pain | 3 | 1 | 2 | 2 | 0 | 0 | 0 | 0 |
Nausea | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Total | 14 | 11 | 20 | 3 | ||||